Advanced search
Publication Cover
Clinical Ophthalmology Volume 15, 2021 - Issue
Submit an article Journal homepage
131
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma

Mayuresh Naik1 Department of Ophthalmology, H.I.M.S.R & H.A.H. Centenary Hospital, New Delhi, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0368-042XView further author information
ORCID Icon,
Monika Kapur2 Department of Ophthalmology, School of Medical Sciences & Research, Sharda University, Greater Noid, Uttar Pradesh, IndiaView further author information
,
VishnuSwarup Gupta1 Department of Ophthalmology, H.I.M.S.R & H.A.H. Centenary Hospital, New Delhi, IndiaView further author information
,
HarinderSingh Sethi3 Department of Ophthalmology, V.M.M.C & Safdarjung Hospital, New Delhi, 110029, IndiaView further author information
&
Kartikeya Srivastava3 Department of Ophthalmology, V.M.M.C & Safdarjung Hospital, New Delhi, 110029, IndiaView further author information
Pages 2683-2692 | Published online: 24 Jun 2021

References

  • Resnikoff S, Pascolini D, Etya D, et al. Global Data on Visual Impairment in the Year 2002. Vol. 82. Bulletin of the World Health Organization; 2004.
  • Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267. doi:10.1136/bjo.2005.081224
  • George R, Ve RS, Vijaya L. Glaucoma in India: estimated burden of disease. J Glaucoma. 2010;19(6):391–397. doi:10.1097/IJG.0b013e3181c4ac5b
  • Gessesse GW, Damji KF. Advanced glaucoma: management pearls. Middle East Afr J Ophthalmol. 2013;20(2):131–141. doi:10.4103/0974-9233.110610
  • VanVeldhuisen Paul C, Ederer F. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440.
  • Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008;115(1123–1129):e3. doi:10.1016/j.ophtha.2007.10.031
  • National Institute for Health and Clinical Excellence (NICE). Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension. Clinical Guidelines CG85, UK National Institute for Health and Clinical Excellence (NICE) Guidelines. Developed by the National Collaborating Centre for Acute Care; 2009.
  • Henderer JD. Disc damage likelihood scale. Br J Ophthalmol. 2006;90(4):395–396. doi:10.1136/bjo.2005.083360
  • Hoddapp E, Parrish RK II, Anderson DR. Clinical Decisions in Glaucoma. Mosby, St. Louis Advanced Glaucoma Intervention Study. 1993.
  • Ramakrishnan R, Nirmalan PK, Krishandas R, et al. Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey. Ophthalmology. 2003;110(8):1484–1490. doi:10.1016/S0161-6420(03)00564-5
  • Peters D, Bengtsson B, Heijl A. Factors associated with lifetime risk of open-angle glaucoma blindness. Acta Ophthalmol. 2014;92(5):421–425. doi:10.1111/aos.12203
  • Sato S, Hirooka K, Nitta E, Ukegawa K, Tsujikawa A. Additive intraocular pressure lowering effects of the rho kinase inhibitor, ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther. 2016;33(9):1628–1634. doi:10.1007/s12325-016-0389-3
  • King AJ, Stead RE, Rotchford AP. Treating patients presenting with advanced glaucoma - should we reconsider current practice? Br J Ophthalmol. 2011;95(9):1185–1192. doi:10.1136/bjo.2010.188128
  • Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev. 2005;18(2):CD004399.
  • Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 1 clinical trials of a selective rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131(10):1288–1295. doi:10.1001/jamaophthalmol.2013.323
  • Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156(4):731–6 e732. doi:10.1016/j.ajo.2013.05.016
  • Tanihara H, Inoue T, Yamamoto T, et al.; K-115 Clinical Study Group. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94(1):e26–34. doi:10.1111/aos.12829
  • Tanihara H, Inoue T, Yamamoto T, et al. Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133(7):755–761. doi:10.1001/jamaophthalmol.2015.0525
  • Tanihara H, Inoue T, Yamamoto T, et al.; K-115 Clinical Study Group. Intra-ocular pressure-lowering effects of a rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a Randomized, Open-Label, Crossover Study. Acta Ophthalmol. 2015;93(4):e254–60. doi:10.1111/aos.12599

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.